 Amie Meditz
Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 22 | 2022 | 2945 | 1.470 |
Why?
| | HIV-1 | 12 | 2022 | 886 | 1.380 |
Why?
| | Receptors, CCR5 | 3 | 2013 | 59 | 1.130 |
Why?
| | Lymph Nodes | 9 | 2017 | 492 | 0.990 |
Why?
| | Anti-HIV Agents | 9 | 2016 | 836 | 0.970 |
Why?
| | Adenine | 6 | 2016 | 301 | 0.810 |
Why?
| | Blood Chemical Analysis | 3 | 2014 | 110 | 0.550 |
Why?
| | Desiccation | 2 | 2014 | 22 | 0.540 |
Why?
| | Organophosphates | 2 | 2016 | 155 | 0.520 |
Why?
| | Raltegravir Potassium | 2 | 2015 | 19 | 0.490 |
Why?
| | Specimen Handling | 2 | 2014 | 182 | 0.480 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2015 | 281 | 0.480 |
Why?
| | Atazanavir Sulfate | 1 | 2015 | 44 | 0.460 |
Why?
| | Genitalia, Female | 1 | 2015 | 41 | 0.460 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 136 | 0.450 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2012 | 42 | 0.450 |
Why?
| | Disease Transmission, Infectious | 2 | 2014 | 68 | 0.440 |
Why?
| | RNA, Viral | 4 | 2013 | 684 | 0.420 |
Why?
| | Postmenopause | 3 | 2013 | 376 | 0.420 |
Why?
| | HLA-DR Antigens | 2 | 2012 | 228 | 0.410 |
Why?
| | Emtricitabine | 7 | 2016 | 204 | 0.410 |
Why?
| | T-Lymphocyte Subsets | 3 | 2015 | 416 | 0.410 |
Why?
| | Organophosphonates | 4 | 2015 | 99 | 0.380 |
Why?
| | Medication Adherence | 3 | 2016 | 505 | 0.370 |
Why?
| | Cervix Uteri | 1 | 2012 | 52 | 0.370 |
Why?
| | Deoxycytidine | 4 | 2015 | 192 | 0.360 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2013 | 1097 | 0.360 |
Why?
| | CD4 Antigens | 1 | 2011 | 141 | 0.340 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2008 | 174 | 0.340 |
Why?
| | Biopsy | 1 | 2014 | 1072 | 0.330 |
Why?
| | Tenofovir | 6 | 2016 | 274 | 0.290 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 501 | 0.290 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 83 | 0.280 |
Why?
| | Viral Load | 5 | 2015 | 495 | 0.280 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 141 | 0.280 |
Why?
| | Sarcoma, Kaposi | 1 | 2007 | 79 | 0.250 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2022 | 386 | 0.240 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2007 | 128 | 0.240 |
Why?
| | Adult | 24 | 2017 | 38393 | 0.240 |
Why?
| | Middle Aged | 21 | 2017 | 33782 | 0.220 |
Why?
| | Leukocytes, Mononuclear | 5 | 2016 | 571 | 0.220 |
Why?
| | Lymphocyte Activation | 4 | 2015 | 1148 | 0.200 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 79 | 0.200 |
Why?
| | CD4 Lymphocyte Count | 2 | 2015 | 280 | 0.190 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2015 | 227 | 0.190 |
Why?
| | Endothelium, Vascular | 3 | 2013 | 935 | 0.180 |
Why?
| | HIV Seropositivity | 1 | 2022 | 126 | 0.180 |
Why?
| | Sex Characteristics | 1 | 2007 | 766 | 0.180 |
Why?
| | Female | 24 | 2017 | 74016 | 0.170 |
Why?
| | Zidovudine | 2 | 2012 | 79 | 0.160 |
Why?
| | Lamivudine | 2 | 2012 | 65 | 0.160 |
Why?
| | Virus Replication | 4 | 2017 | 526 | 0.160 |
Why?
| | HIV Seronegativity | 2 | 2010 | 30 | 0.150 |
Why?
| | Humans | 32 | 2022 | 138972 | 0.140 |
Why?
| | Vascular Stiffness | 2 | 2013 | 443 | 0.140 |
Why?
| | Chromatography, Liquid | 3 | 2014 | 449 | 0.140 |
Why?
| | Sex Factors | 3 | 2013 | 2050 | 0.140 |
Why?
| | Rectum | 2 | 2016 | 188 | 0.140 |
Why?
| | Dried Blood Spot Testing | 2 | 2016 | 121 | 0.140 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 2 | 2015 | 89 | 0.140 |
Why?
| | Viral Tropism | 1 | 2017 | 34 | 0.130 |
Why?
| | Male | 20 | 2017 | 68250 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 556 | 0.130 |
Why?
| | Genitalia | 1 | 2016 | 33 | 0.130 |
Why?
| | Dendritic Cells | 2 | 2010 | 491 | 0.120 |
Why?
| | Polyphosphates | 1 | 2016 | 43 | 0.120 |
Why?
| | Germinal Center | 1 | 2016 | 64 | 0.120 |
Why?
| | Biological Assay | 1 | 2016 | 129 | 0.120 |
Why?
| | Blood | 1 | 2015 | 113 | 0.110 |
Why?
| | Vasodilation | 3 | 2013 | 509 | 0.110 |
Why?
| | Young Adult | 10 | 2016 | 13371 | 0.110 |
Why?
| | Cohort Studies | 3 | 2013 | 5744 | 0.100 |
Why?
| | Homosexuality, Male | 1 | 2014 | 193 | 0.100 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 166 | 0.100 |
Why?
| | Erythrocytes | 2 | 2016 | 701 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 243 | 0.100 |
Why?
| | Estradiol | 2 | 2013 | 525 | 0.100 |
Why?
| | Estrogens | 2 | 2013 | 370 | 0.090 |
Why?
| | Immunoglobulin G | 2 | 2013 | 898 | 0.090 |
Why?
| | Health | 1 | 2012 | 84 | 0.090 |
Why?
| | Palatine Tonsil | 3 | 2017 | 53 | 0.090 |
Why?
| | Cytidine Triphosphate | 2 | 2012 | 18 | 0.090 |
Why?
| | Thymine Nucleotides | 2 | 2012 | 19 | 0.090 |
Why?
| | Receptors, HIV | 1 | 2011 | 25 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 433 | 0.090 |
Why?
| | Antacids | 1 | 2010 | 16 | 0.080 |
Why?
| | Pyrrolidinones | 1 | 2010 | 30 | 0.080 |
Why?
| | Geography | 1 | 2011 | 200 | 0.080 |
Why?
| | Disease Susceptibility | 1 | 2012 | 349 | 0.080 |
Why?
| | North America | 1 | 2011 | 304 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2012 | 329 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 251 | 0.080 |
Why?
| | Viremia | 1 | 2010 | 149 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 236 | 0.080 |
Why?
| | Myeloid Cells | 1 | 2010 | 151 | 0.080 |
Why?
| | Menopause | 1 | 2012 | 326 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1047 | 0.070 |
Why?
| | Aged | 6 | 2017 | 24172 | 0.070 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 25 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2015 | 10921 | 0.070 |
Why?
| | Anti-Retroviral Agents | 1 | 2010 | 244 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1244 | 0.070 |
Why?
| | B-Lymphocytes | 1 | 2013 | 855 | 0.070 |
Why?
| | Zimbabwe | 1 | 2007 | 59 | 0.070 |
Why?
| | Brachial Artery | 3 | 2013 | 202 | 0.070 |
Why?
| | Sweating | 1 | 2007 | 41 | 0.060 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.060 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 193 | 0.060 |
Why?
| | Granulocytes | 1 | 2006 | 85 | 0.060 |
Why?
| | Gender Identity | 1 | 2007 | 126 | 0.060 |
Why?
| | HIV | 1 | 2007 | 246 | 0.060 |
Why?
| | Fever | 1 | 2007 | 305 | 0.060 |
Why?
| | DNA | 1 | 2012 | 1441 | 0.060 |
Why?
| | Hematocrit | 2 | 2016 | 103 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2017 | 4182 | 0.050 |
Why?
| | Antigens, CD | 1 | 2007 | 537 | 0.050 |
Why?
| | Macaca mulatta | 2 | 2015 | 186 | 0.050 |
Why?
| | Adolescent | 6 | 2016 | 21581 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2007 | 1497 | 0.050 |
Why?
| | Cell Movement | 1 | 2007 | 969 | 0.050 |
Why?
| | Temperature | 2 | 2016 | 660 | 0.040 |
Why?
| | Apoptosis | 1 | 2010 | 2551 | 0.040 |
Why?
| | Weight Loss | 1 | 2007 | 783 | 0.040 |
Why?
| | Carotid Arteries | 2 | 2013 | 195 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2022 | 451 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 2058 | 0.040 |
Why?
| | Dideoxynucleotides | 2 | 2012 | 16 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2016 | 254 | 0.040 |
Why?
| | Risk Factors | 2 | 2012 | 10385 | 0.040 |
Why?
| | Drug Interactions | 2 | 2010 | 404 | 0.040 |
Why?
| | B7-H1 Antigen | 2 | 2013 | 216 | 0.040 |
Why?
| | Prospective Studies | 3 | 2016 | 7661 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 111 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3313 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 7 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 23 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 184 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 36 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 96 | 0.030 |
Why?
| | Methanol | 1 | 2016 | 43 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1804 | 0.030 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 57 | 0.030 |
Why?
| | Solutions | 1 | 2016 | 168 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 90 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 731 | 0.030 |
Why?
| | Time Factors | 2 | 2016 | 6869 | 0.030 |
Why?
| | Phenotype | 2 | 2016 | 3143 | 0.030 |
Why?
| | Etanercept | 1 | 2013 | 59 | 0.030 |
Why?
| | Calibration | 1 | 2013 | 149 | 0.020 |
Why?
| | Drug Stability | 1 | 2013 | 164 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 173 | 0.020 |
Why?
| | Premenopause | 1 | 2013 | 132 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 488 | 0.020 |
Why?
| | Healthy Volunteers | 1 | 2013 | 208 | 0.020 |
Why?
| | Half-Life | 1 | 2012 | 146 | 0.020 |
Why?
| | Water | 1 | 2016 | 461 | 0.020 |
Why?
| | Interleukins | 1 | 2013 | 248 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2010 | 11 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 22 | 0.020 |
Why?
| | Plasma | 1 | 2012 | 220 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 93 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 358 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1103 | 0.020 |
Why?
| | Women's Health | 1 | 2012 | 372 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 695 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 748 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2016 | 1994 | 0.020 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 35 | 0.020 |
Why?
| | Gene Products, gag | 1 | 2007 | 38 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 85 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 509 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 166 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 5 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 225 | 0.020 |
Why?
| | Blood Pressure | 1 | 2013 | 1737 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2007 | 327 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 769 | 0.010 |
Why?
| | Ligands | 1 | 2007 | 666 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 413 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2850 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2176 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 852 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1192 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2007 | 787 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1767 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1985 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1730 | 0.010 |
Why?
| | Animals | 2 | 2015 | 37243 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 5530 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 910 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2007 | 2480 | 0.010 |
Why?
| | Child | 1 | 2017 | 21936 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 4095 | 0.010 |
Why?
| | Inflammation | 1 | 2006 | 2853 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 5092 | 0.010 |
Why?
|
|
Meditz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|